Securities code: C.Q.Pharmaceutical Holding Co.Ltd(000950) securities abbreviation: C.Q.Pharmaceutical Holding Co.Ltd(000950) Announcement No.: 2022010 C.Q.Pharmaceutical Holding Co.Ltd(000950)
Announcement on abnormal fluctuation of stock price
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Important:
1. The daily closing price of the company’s shares has deviated from the value by more than 20% in two consecutive trading days, which belongs to abnormal fluctuation of stock trading.
2. After the company’s self-examination and verification with the controlling shareholder and actual controller, there are no major matters that should be disclosed but not disclosed.
3. The company is concerned that investors recently pay attention to the concept of assisted reproduction and three births. Hubei Dingkang Biotechnology Co., Ltd., a holding subsidiary of the company, is mainly engaged in medical consumables and devices in the whole process of assisted reproductive technology. In 2020, the income of assisted reproduction business accounted for about 0.6% of the company’s annual operating income, and the net profit of assisted reproduction business accounted for about 6.8% of the company’s net profit, which was relatively small as a whole; There will be no major business adjustment in the assisted reproduction sector in 2021, and there will be no large fluctuations in income and profits.
4. The company disclosed the announcement on the completion of the implementation of the share reduction plan for shareholders holding more than 5% and the pre disclosure announcement on the share reduction plan for shareholders holding more than 5% on March 3, 2022.
Please pay attention to investment risks.
1、 Abnormal fluctuation of stock price trading
C.Q.Pharmaceutical Holding Co.Ltd(000950) (hereinafter referred to as “the company” or “the company”) (stock abbreviation: C.Q.Pharmaceutical Holding Co.Ltd(000950) , stock code: C.Q.Pharmaceutical Holding Co.Ltd(000950) ) on March 4 and March 7, 2022, the cumulative deviation of the closing price increase exceeds 20%. According to the relevant provisions of the trading rules of Shenzhen stock exchange, it is an abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
1. According to the company’s self inspection, the company’s current production and operation activities are normal, and there are no major matters affecting the abnormal fluctuation of the company’s stock trading price.
2. Chongqing pharmaceutical and Health Industry Co., Ltd., the controlling shareholder of the company, replied and confirmed that the controlling shareholder and the actual controller of the company did not have arrangements involving C.Q.Pharmaceutical Holding Co.Ltd(000950) the merger and reorganization, share issuance, debt restructuring, business restructuring, asset divestiture, asset injection and other major matters.
3. The company is concerned about the concept of assisted reproduction and three births. Hubei Dingkang Biotechnology Co., Ltd., a holding subsidiary of the company, is mainly engaged in medical consumables and devices in the whole process of assisted reproductive technology. In 2020, the income of assisted reproduction business accounted for about 0.6% of the company’s annual operating income, and the net profit of assisted reproduction business accounted for about 6.8% of the company’s net profit, which was relatively small as a whole; There will be no major business adjustment in the assisted reproduction sector in 2021, and there will be no large fluctuations in income and profits.
The company has not found any other media reports or market rumors requiring clarification or response; The company has not found any other unpublished material information that may have a great impact on the company’s stock trading price.
4. During the abnormal fluctuation of stock trading, the controlling shareholders and actual controllers of the company did not buy or sell the company’s shares, and the company did not find any other major events that may have a great impact on the company’s share price.
5. The company disclosed the announcement on the completion of the implementation of the share reduction plan for shareholders holding more than 5% and the pre disclosure announcement on the share reduction plan for shareholders holding more than 5% on March 3, 2022. The information disclosed in the early stage does not need to be corrected or supplemented.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that, except for the information disclosed by the company, the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has information that should be disclosed but not disclosed according to the stock listing rules of Shenzhen Stock Exchange and has a great impact on the stock trading price of the company; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Necessary risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2. The company disclosed the performance forecast for 2021 on January 15, 2022. As of the disclosure date of this announcement, there is no situation that should be corrected in the performance forecast. The forecast data of 2021 annual performance forecast is the preliminary estimation result of the company. The specific financial data shall be subject to the 2021 annual report disclosed by the company.
3. China Securities Journal, securities times, Securities Daily, Shanghai Securities News and cninfo (www.cn. Info. Com. CN.) As the information disclosure media designated by the company, all information of the company shall be subject to the information published in the above designated media. Investors are invited to invest rationally and pay attention to risks.
It is hereby announced
C.Q.Pharmaceutical Holding Co.Ltd(000950) board of directors March 8, 2022
